Our findings demonstrate that SOX30 is a special tumor-metastasis suppressor and early-stage favorable prognostic factor by directly repressing Wnt/β-catenin (CTNNB1) signaling activity only in ADC patients, providing novel insights into and specifically potential molecular-targeted strategy for NSCLC therapy. This evidence concerns the gene SOX30 and AIDS dementia complex.